"Quick, simple, and friendly": Understanding the acceptability and accessibility of a nurse and peer-led, mobile model of hepatitis C care adjacent to community corrections in Australia.
Griffin S, Walker S, Holmes JA, Reid B, Callus A, Belzer M, Dicka J, Papaluca T, Craigie A, Schroeder S, Lancaster K, Hellard M, Stoové M, Thompson AJ, Winter RJ
Hepatitis C
Disproportionate, differential and targeted treatment: people who use drugs' experiences of policing during the COVID-19 pandemic.
Walker S, Rathnayake K, Dietze P, Higgs P, Ward B, Hellard M, Doyle J, Stoove M, Maher L
COVID-19
Predictors of treatment outcomes for Hepatitis C infection in a nationwide elimination program in Iceland: The treatment as prevention for Hepatitis C (TraP HepC) study.
Olafsson S, Love TJ, Fridriksdottir RH, Tyrfingsson T, Runarsdottir V, Hansdottir I, Bergmann OM, Björnsson ES, Johannsson B, Sigurdardottir B, Löve A, Baldvinsdottir GE, Thordardottir M, Hernandez UB, Heimisdottir M, Hellard M, Gottfredsson M, TraP Hep C working group
Hepatitis C
Cost-Effectiveness of Treating Hepatitis C in Clients on Opioid Agonist Therapy in Community Pharmacies Compared to Primary Healthcare in Australia.
Ginnane JF, Scott N, Radley A, Dillon JF, Hellard M, Doyle J
Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey.
Maher L, Wand H, Heard S, Starr M, Zolala F, Kemp R, Cunningham P, Drummer H, Hellard M, Kaldor J, Dore G
Hepatitis C Injecting Drug Use
Availability of point-of-care HBV tests in resource-limited settings.
Lau DTY, Jackson K, Picchio CA, Kramvis A, Sonderup M, Lemoine M, Matthews G, Howell J, Coffin CS, Hellard M, Lee AU, Anderson DA, Kerth HA, Lee EE, Tavis JE, Dandri M, Revill PA, Spearman CW, Penicaud C, Levrero M, El-Sayed M, ICE-HBV POC Model in Resource Limited Settings working group
Hepatitis B